NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE255581 Query DataSets for GSE255581
Status Public on Feb 13, 2024
Title GDNF/GFRA1 signaling contributes to chemo- and radioresistance in glioblastoma
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Glioblastoma (GBM) is the most common primary brain tumor in adults, characterized by an inherent aggressivity and resistance to treatment leading to poor prognoses. While some resistance mechanisms have been elucidated, a deeper understanding of these mechanisms is needed to increase therapeutic efficacy. In this study we first discovered glial-cell derived neurotrophic factor (GDNF) to be upregulated in patient-derived glioblastoma spheroid cultures after chemotherapeutic temozolomide (TMZ) treatment, through RNA-Seq experiments. Therefore, we investigated the role of the GDNF/GDNF receptor alpha 1 (GFRA1) signaling pathway as a resistance mechanism to chemotherapy with temozolomide and lomustine as well as irradiation using patient-derived glioblastoma spheroid cultures. With qPCR experiments we showed a consistent upregulation of GDNF and its primary receptor GFRA1 following all three lines of treatment. Moreover, CRISPR/Cas9 knock-outs of GDNF in two patient-derived models sensitized these cells to chemotherapy treatment, but not radiotherapy. The increased sensitivity was completely reversed by the addition of exogeneous GDNF, confirming the key role of this factor in chemoresistance. Finally, a CRISPR KO of GFRA1 demonstrated a similar increased sensitivity to temozolomide and lomustine treatment, as well as radiotherapy. Together, our findings support the role of the GDNF/GFRA1 signaling pathway in glioblastoma chemo and radioresistance.
 
Overall design To uncover potential genes of interest in glioblastoma treatment resistance we used 3 patient-derived primary glioblastoma cell lines, treated each one with either the alkylating agent Temozolomide or a DMSO control and compared control/post treatment gene expression through an RNA-Seq experiment.

***************************************************************
no raw files due to patient privacy issues (RNASeq experiment was done on patient-derived samples)
***************************************************************
 
Contributor(s) Mark B, Martin T, Mads T
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Feb 12, 2024
Last update date Feb 13, 2024
Contact name Inès CN Avenel
E-mail(s) ines.clemence.nati.avenel@regionh.dk
Organization name BRIC
Street address Ole Maaløes Vej 5
City København Nv
ZIP/Postal code 2200
Country Denmark
 
Platforms (1)
GPL18460 Illumina HiSeq 1500 (Homo sapiens)
Samples (6)
GSM8075531 T78 GBM cells afer TMZ treatment
GSM8075532 Control T78 GBM cells
GSM8075533 T86 GBM cells after TMZ treatment
Relations
BioProject PRJNA1075663

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE255581_TMZ_RNAseq_cpm_matrix.xlsx 1.3 Mb (ftp)(http) XLSX
GSE255581_processed_file_-_other_format.txt.gz 539.8 Kb (ftp)(http) TXT
Raw data not provided for this record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap